CeNeRx BioPharma, Inc., a biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system, today announced it has signed an agreement with PharmaNess Neuroscience giving CeNeRx the rights to a series of novel cannabinoid compounds that selectively target the CB1 and CB2 cannabinoid receptors.
From: biz.yahoo.com
Wednesday, May 30, 2007
CeNeRx Announces Agreement With PharmaNess Neuroscience to Develop Novel Cannabinoid Compounds
Subscribe to:
Post Comments (Atom)
![Digitalpoint Geo Tracking [Enabled]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vtZsDjnIofTCqmpG-s6NP_uaDzNmbL-wKalHScxz2i455pyMjdPSxFfNHxqhKY5--c4tB3rvP1oxgSHDfvI47G4G0fsA=s0-d)
![PingOmatic AutoDiscovery [Enabled]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vD8jhQpcEnPNC9qMY1NzxEP4PLawb_1jxlx6eWgwNQXC3ZBhh87gIsumjk438xl0xGQwDGA7IR0NJnvNKT9zb3h9Ac6kntvH7DCHnb8ZByk-xJU3Hfqh57dL0zpPfy=s0-d)
![Made with Palestinian Efforts [True]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_uPTCbnGVfV2FZKEGvN_t2MM0kie6hZVos6buAcxve-4dgAQRw09lwlwzqmVrQTBbs9ac1piXmw2WSuQnO2jUo3_OBVzJ9x3UC5X-jCGdY4xtMefNCABBmRrg=s0-d)
No comments:
Post a Comment